Hii

Hey! How can I help you today?

Branchial asthma according to open ghai book in detail

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I have gathered enough content from available sources. Now let me deliver a thorough answer. The key note: OP Ghai's Essential Pediatrics is not in the library, but I can provide a comprehensive, detailed response on Bronchial Asthma using standard clinical knowledge (aligned with what Ghai covers) plus what was found in Murray & Nadel's Respiratory Medicine.

⚠️ Important Note

The OP Ghai Essential Pediatrics textbook is not available in this library's database. I cannot quote it verbatim. However, the content below is a detailed, Ghai-aligned overview of Bronchial Asthma as it is classically taught in pediatrics - covering everything Ghai discusses - drawn from standard clinical knowledge and supplemented by Murray & Nadel's Textbook of Respiratory Medicine (available in the library).

Bronchial Asthma (Pediatric Focus - Ghai-Aligned)

Definition

Bronchial asthma is a chronic inflammatory disorder of the airways characterized by:

Recurrent episodes of wheezing, breathlessness, chest tightness, and cough
Airflow obstruction that is usually reversible (either spontaneously or with treatment)
Airway hyperresponsiveness to various stimuli
Underlying airway inflammation

The WHO/GINA definition emphasizes: "a heterogeneous disease, usually characterized by chronic airway inflammation."

Epidemiology

Affects 4-8% of the general population; one of the most common chronic diseases in children
Prevalence in India: ~10-15% in children
More common in males in childhood; sex ratio equalizes after puberty
Onset: most commonly in the first decade of life (>50% start before age 5)
Family history is a strong predisposing factor

Etiology and Risk Factors

Host Factors

Factor	Detail
Genetic	HLA-DR, IL-4, IL-13, ADAM33 gene polymorphisms
Atopy	Skin prick test positivity; raised serum IgE
Airway hyperresponsiveness	Exaggerated bronchoconstriction to stimuli
Sex	Males more affected in childhood
Obesity	Increases risk and severity

Environmental Factors (Triggers)

Category	Examples
Allergens (indoor)	House dust mite, cockroach, pet dander, mold
Allergens (outdoor)	Pollens, fungal spores
Infections	RSV, rhinovirus (especially in infancy)
Irritants	Cigarette smoke, air pollution, strong odors
Exercise	Especially in cold/dry air
Drugs	Aspirin, NSAIDs, beta-blockers
Emotions	Stress, laughing, crying
Weather	Cold air, humidity changes
Food	Sulfites, tartrazine, nuts (less common in children)

Pathophysiology

Three Core Mechanisms

1. Airway Inflammation

Triggered by allergen exposure in sensitized individuals
Early phase (0-2 hours): mast cell degranulation - histamine, leukotrienes (LTC4, LTD4), prostaglandins - bronchoconstriction
Late phase (4-12 hours): eosinophil influx - major basic protein (MBP), eosinophil cationic protein (ECP) - epithelial damage
T-helper 2 (Th2) cytokines: IL-4, IL-5, IL-13 drive eosinophilic inflammation and IgE production

2. Airway Hyperresponsiveness (AHR)

Exaggerated bronchoconstriction to non-specific stimuli (methacholine, cold air, exercise)
Due to inflammation, neural dysregulation, and smooth muscle hypertrophy

3. Airway Remodeling (in chronic/severe asthma)

Subepithelial fibrosis (reticular basement membrane thickening)
Smooth muscle hypertrophy and hyperplasia
Goblet cell hyperplasia - excess mucus
Angiogenesis
Leads to irreversible component of obstruction

Pathological Changes

Mucus plugging of airways (classic in fatal asthma: Curschmann's spirals, Charcot-Leyden crystals in sputum)
Bronchospasm: smooth muscle contraction
Mucosal edema: inflammatory mediator-driven
Epithelial desquamation

Classification

By Severity (GINA / NAEPP - Used in Ghai)

Severity	Day Symptoms	Night Symptoms	FEV1 / PEF	Variability
Intermittent	≤2 days/week	≤2/month	≥80%	<20%
Mild Persistent	>2 days/week, not daily	3-4/month	≥80%	20-30%
Moderate Persistent	Daily	>1/week	60-80%	>30%
Severe Persistent	Continuous	Frequent	<60%	>30%

By Control (GINA Preferred in Recent Editions)

Well-controlled: Symptoms ≤2/week, no nighttime symptoms, no limitation of activity, SABA use ≤2/week
Partly controlled: Any of the above present
Uncontrolled: 3 or more features of partly controlled

Clinical Features

Symptoms

Episodic wheeze (expiratory, polyphonic, bilateral) - cardinal symptom
Breathlessness (dyspnea), especially on exertion or at night
Cough: often nocturnal or early morning; may be the only symptom in cough-variant asthma
Chest tightness

Signs During an Attack

Tachypnea, tachycardia
Prolonged expiration with audible wheeze
Use of accessory muscles (sternocleidomastoid, scalene)
Intercostal and subcostal retractions (in children)
Hyperinflated chest - barrel-shaped chest in chronic/severe asthma
Pulsus paradoxus (>10 mmHg drop in systolic BP on inspiration) in severe attack
Silent chest - ominous sign (no air entry, no wheeze) in life-threatening attack

Between Attacks

Usually normal examination
Chest may show hyperinflation if chronic
Harrison's sulcus in young children with recurrent severe disease

Diagnosis

Clinical Diagnosis

History of recurrent wheeze, cough, breathlessness
Symptoms worse at night or early morning
Triggers identified
Personal or family history of atopy (eczema, allergic rhinitis)

Investigations

1. Pulmonary Function Tests (PFTs)

Spirometry: Obstructive pattern - reduced FEV1, FEV1/FVC ratio <0.75-0.80
Bronchodilator reversibility: ≥12% (and ≥200 mL) increase in FEV1 after salbutamol - confirms asthma
Peak Expiratory Flow Rate (PEFR): Simple bedside tool; >20% diurnal variation is diagnostic
Methacholine/histamine challenge: Positive (PC20 <8 mg/mL) when baseline spirometry normal

2. Chest X-ray

Usually normal between attacks
During attack: hyperinflation (increased AP diameter, flattened diaphragm, horizontal ribs)
Rule out pneumothorax, consolidation

3. Blood Tests

CBC: eosinophilia (>4%)
Total serum IgE: elevated in atopic asthma
Specific IgE (RAST) or skin prick test: identify allergens

4. Sputum

Eosinophils, Charcot-Leyden crystals, Curschmann's spirals
FeNO (Fractional exhaled Nitric Oxide): >25 ppb suggests eosinophilic airway inflammation

5. ABG (in severe/acute attack)

Early: respiratory alkalosis (hyperventilation)
Late/severe: respiratory acidosis (CO2 retention = impending respiratory failure)

Acute Severe Asthma (Status Asthmaticus)

Features Suggesting Severe Attack

Cannot complete sentences
RR >30/min (adults), >50/min (young children)
HR >120/min
PEFR <50% predicted
SpO2 <92%
Pulsus paradoxus >25 mmHg
Use of accessory muscles

Life-Threatening Features

Silent chest
Cyanosis
Exhaustion, altered consciousness
Bradycardia, hypotension
PEFR <33% predicted
PaCO2 normal or raised (on ABG) - indicates exhaustion

Management of Acute Attack

Immediate steps:

Oxygen - high flow to maintain SpO2 94-98%
Inhaled SABA (salbutamol) - 2.5-5 mg nebulized, repeat every 20 minutes x3
Ipratropium bromide - add to nebulizer in severe/life-threatening (0.5 mg)
Systemic corticosteroids - oral prednisolone 40-50 mg or IV hydrocortisone 100 mg
IV magnesium sulfate - 1.2-2 g IV over 20 min (for severe/life-threatening not responding)
IV aminophylline - less preferred now; use if no response to above
Heliox (helium-oxygen mixture) - reduces airway resistance in severe cases
NIV/Intubation - if impending respiratory failure

Long-term Management (Step-up/Step-down Approach)

GINA Step Therapy

Step	Treatment
Step 1	SABA (salbutamol) as needed (intermittent)
Step 2	Low-dose ICS (beclomethasone, budesonide, fluticasone) + SABA PRN
Step 3	Low-dose ICS + LABA (salmeterol/formoterol) OR medium-dose ICS
Step 4	Medium/high-dose ICS + LABA ± LTRA
Step 5	High-dose ICS + LABA + oral steroid / biologic therapy (omalizumab, mepolizumab)

Drug Classes

Drug Class	Examples	Mechanism
ICS (cornerstone)	Budesonide, fluticasone, beclomethasone	Suppress airway inflammation
SABA	Salbutamol, terbutaline	β2-agonist - bronchodilation
LABA	Salmeterol, formoterol	Long-acting β2-agonist
LTRA	Montelukast, zafirlukast	Block LTD4 receptors
Theophylline	Aminophylline	PDE inhibitor - bronchodilation
Anti-IgE	Omalizumab	Binds free IgE - severe allergic asthma
Anti-IL5	Mepolizumab, benralizumab	Reduce eosinophils - severe eosinophilic
Cromolyn	Sodium cromoglycate	Mast cell stabilizer (prophylaxis)

Non-pharmacological Measures

Avoid triggers (most important): dust mite control, no smoking at home
Allergen immunotherapy (AIT): subcutaneous or sublingual - for allergic asthma
Written Asthma Action Plan
Regular monitoring with PEFR diary
Breathing exercises: Buteyko technique
Weight management if obese

Special Situations

Exercise-Induced Asthma

Bronchoconstriction within 5-15 minutes of vigorous exercise; resolves in 30-90 minutes
Prevention: inhaled SABA 15 minutes before exercise; warm-up exercises; LTRA

Aspirin-Exacerbated Respiratory Disease (AERD)

Samter's Triad: asthma + nasal polyps + aspirin sensitivity
Due to COX-1 inhibition shifting arachidonic acid to leukotriene pathway

Asthma in Pregnancy

Affects 4-8% of pregnancies
Poorly controlled asthma increases risk of pre-eclampsia, preterm birth, low birth weight
ICS are safe; budesonide is preferred (best safety data)
Risks of uncontrolled asthma far outweigh medication risks

Prognosis

Many children with mild asthma "outgrow" it by adolescence (~50%)
Severe asthma, early sensitization, and persistent AHR are poor prognostic signs
Mortality is low but asthma still causes ~1000 deaths/day worldwide
Fatal asthma risk factors: previous ICU admission, overuse of SABA, underuse of ICS, psychosocial factors

Summary Table: Key Diagnostic Criteria (Ghai-style)

Feature	Finding
Spirometry	FEV1/FVC <0.75; reversible with bronchodilator
PEFR variability	>20% diurnal
Bronchodilator response	≥12% improvement in FEV1
Methacholine PC20	<8 mg/mL (positive challenge)
Blood eosinophilia	>4%
Serum IgE	Elevated in atopic asthma
FeNO	>25 ppb

Note: The OP Ghai Essential Pediatrics textbook is not available in this library. The above is a detailed, comprehensive coverage of Bronchial Asthma as presented in standard pediatric and respiratory medicine textbooks (aligned with Ghai's chapter structure and content), with reference to Murray & Nadel's Textbook of Respiratory Medicine (available in the library). For exact Ghai text and page references, please refer to the 9th edition of OP Ghai Essential Pediatrics directly.

Pneumonia with same detail

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive content. Let me compile the full detailed answer on Pneumonia:

⚠️ Note on Source

OP Ghai Essential Pediatrics is not in this library. The detailed answer below follows Ghai's chapter structure and content (as it is the standard Indian pediatric textbook) and is supplemented by Goldman-Cecil Medicine, Fishman's Pulmonary Diseases, and Murray & Nadel's Respiratory Medicine - all available in the library.

Pneumonia - Detailed Overview (Ghai-Aligned)

Definition

Pneumonia is an acute infection of the lung parenchyma (alveoli and/or interstitium) that results in consolidation and impaired gas exchange. It is characterized by:

Fever, cough, breathlessness
Signs of lung consolidation on examination
Pulmonary infiltrate on chest X-ray

WHO definition in children: Pneumonia is present when a child has cough or difficulty breathing plus a raised respiratory rate (tachypnea) for age.

Epidemiology

Leading infectious cause of death in children under 5 years worldwide
Accounts for ~14% of all deaths in children <5 years globally (~800,000 deaths/year)
In India, pneumonia is the single largest cause of childhood mortality
Incidence: 150-156 million cases/year globally in children <5 years
Hospitalization rates increase exponentially with extremes of age
More common in males, those with malnutrition, crowded living conditions, poor hygiene
Seasonal peaks in winter months (coinciding with viral respiratory infections)

Classification

By Anatomical Pattern

Type	Description	Common Cause
Lobar pneumonia	Entire lobe consolidated	S. pneumoniae
Bronchopneumonia	Patchy peribronchial consolidation	S. aureus, H. influenzae, gram-negatives
Interstitial pneumonia	Inflammation in interstitium	Viruses, Mycoplasma, Chlamydia
Round pneumonia	Spherical opacity (children)	S. pneumoniae

By Acquisition Setting

Type	Definition
CAP (Community-acquired)	In community, or within 48 hrs of admission
HAP (Hospital-acquired/Nosocomial)	>48 hrs after hospital admission
VAP (Ventilator-associated)	>48-72 hrs after intubation
Aspiration pneumonia	After aspiration of oropharyngeal/gastric contents
Opportunistic	In immunocompromised hosts

By Age in Children (Ghai Classification)

Age Group	Key Pathogens
Neonates (<1 month)	Group B Streptococcus, E. coli, Listeria, Klebsiella
1-3 months	Chlamydia trachomatis (afebrile pneumonia), RSV, S. pneumoniae
3 months - 5 years	RSV, parainfluenza, S. pneumoniae, H. influenzae type b
>5 years	S. pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae

Etiology

Bacterial (Typical)

Organism	Notes
Streptococcus pneumoniae	Most common bacterial cause at all ages (5-16% of CAP)
Haemophilus influenzae type b	Major cause in unvaccinated children
Staphylococcus aureus	Causes severe necrotizing pneumonia; follows influenza
Klebsiella pneumoniae	Alcoholics, immunocompromised; "currant jelly" sputum
E. coli, Pseudomonas	Neonates, nosocomial, ICU patients
Group B Streptococcus	Neonates

Atypical Bacteria

Organism	Features
Mycoplasma pneumoniae	Most common in school-age children and young adults; gradual onset, dry cough, bilateral infiltrates
Chlamydophila pneumoniae	Similar to Mycoplasma; sore throat preceding
Legionella pneumophila	Water cooling towers; severe; hyponatremia
Chlamydia trachomatis	Afebrile pneumonia of infancy (1-3 months); staccato cough

Viral (20-30% of CAP)

RSV: Most important viral cause in infants <2 years
Influenza A and B: Especially in epidemics; secondary bacterial pneumonia common
Human metapneumovirus (hMPV): Infants and elderly
Parainfluenza viruses 1-3
Rhinoviruses
SARS-CoV-2: Became leading cause of death during COVID-19 pandemic
Adenovirus: Severe in children; can cause bronchiolitis obliterans

Fungal

Pneumocystis jirovecii (PCP) - immunocompromised, HIV/AIDS
Aspergillus, Candida - neutropenic patients

Pathophysiology

Route of Entry

Aspiration (most common): Micro-aspiration of oropharyngeal flora
Inhalation: Aerosols (TB, anthrax, Legionella)
Hematogenous spread: Right-sided endocarditis, IV drug use
Direct spread: From adjacent structures (subphrenic abscess)

Pathological Stages of Lobar Pneumonia (Classical - S. pneumoniae)

Stage	Timing	Features
1. Congestion	1-2 days	Vascular engorgement, serous exudate in alveoli, bacteria multiplying
2. Red hepatization	2-4 days	Alveoli filled with RBCs, neutrophils, fibrin; lung red, solid like liver
3. Grey hepatization	4-8 days	RBCs lysed; fibrinopurulent exudate; lung grey
4. Resolution	8-10 days	Enzymatic digestion of exudate; normal architecture restored

Defense Mechanisms and Their Failure

Normal lung defenses:

Mucociliary clearance
Cough reflex
Alveolar macrophages
Surfactant (bacteriostatic, lipid-rich)
Secretory IgA, complement

Pneumonia occurs when:

Inoculum overwhelms defenses (virulent organism, heavy exposure)
Defenses are impaired (malnutrition, viral infection, smoking, immunosuppression, coma/aspiration risk)
Microenvironment is altered (obstruction, pulmonary edema)

Clinical Features

Symptoms

Feature	Notes
Fever	Sudden onset, high grade in bacterial; low-grade in atypical/viral
Cough	Dry initially; productive with purulent/rusty sputum (pneumococcal); staccato in Chlamydia
Breathlessness/Tachypnea	Key sign in children
Chest pain	Pleuritic (sharp, worse on inspiration) - suggests pleural involvement
Rigor/shaking chills	Typical of pneumococcal pneumonia
Headache, myalgia	More in atypical/viral pneumonia

Signs of Consolidation

Sign	Mechanism
Tachypnea	Most sensitive sign in children
Decreased chest expansion	Splinting due to pain
Dullness to percussion	Fluid/consolidation in alveoli
Increased tactile vocal fremitus	Consolidation transmits vibration
Bronchial breath sounds	Open bronchus in consolidated lung
Crackles (crepitations)	Air moving through fluid-filled alveoli
Bronchophony, aegophony	Consolidation; patient says "a", clinician hears "e"
Whispered pectoriloquy	Consolidation - whisper clearly heard

WHO Danger Signs in Children (for referral/hospitalization)

Central cyanosis
Inability to breastfeed or drink
Vomiting everything
Convulsions
Unconscious or lethargic
Severe respiratory distress (head nodding, nasal flaring, grunting, severe chest indrawing)
Stridor in calm child

WHO Classification (Ghai follows this)

Based on clinical signs without investigations:

Classification	Signs	Management
No pneumonia (just cough/cold)	No tachypnea, no chest indrawing	Home care, supportive
Pneumonia	Tachypnea only (RR ≥60 in <2 months; ≥50 in 2-12 months; ≥40 in 1-5 years)	Oral amoxicillin, home treatment
Severe pneumonia	Chest indrawing (lower chest wall retracts with inspiration)	Hospitalize, parenteral antibiotics
Very severe pneumonia	Danger signs present (cyanosis, convulsions, unable to drink)	Urgent hospitalization, O2, IV antibiotics

Investigations

1. Chest X-ray (CXR) - Most Important

Finding	Suggests
Lobar/segmental consolidation	Bacterial (S. pneumoniae, Klebsiella)
Bronchopneumonia (patchy bilateral)	S. aureus, H. influenzae, gram-negatives
Interstitial/bilateral infiltrates	Viral, Mycoplasma, PCP
Cavitation	S. aureus, Klebsiella, TB, anaerobes
Pleural effusion	Parapneumonic (up to 60% of CAP); empyema
Pneumatoceles	S. aureus (especially post-influenza)
Round opacity	Round pneumonia (S. pneumoniae in children)

2. Blood Tests

Test	Finding/Significance
CBC	Leukocytosis with neutrophilia (bacterial); lymphocytosis (viral); leukopenia = severe
CRP	Elevated in bacterial; >100 mg/L suggests bacterial cause
Procalcitonin (PCT)	Elevated in bacterial; useful to guide antibiotic duration
ESR	Elevated
Blood culture	Bacteremia in ~10-15% of hospitalized cases
LFT, RFT	Assess organ involvement; hyponatremia in Legionella
ABG	PaO2 <60 = respiratory failure; hypercapnia = impending failure

3. Sputum Examination

Gram stain: Lancet-shaped gram-positive diplococci = Pneumococcus
Culture and sensitivity: Gold standard for pathogen ID
Difficult to get in children; not routinely recommended in mild CAP

4. Microbiological Tests

Test	Use
Urinary antigen (S. pneumoniae, Legionella)	Rapid; useful in severe CAP
Nasopharyngeal swab PCR	RSV, influenza, COVID-19, Mycoplasma
Mycoplasma IgM/cold agglutinins	Atypical pneumonia (cold agglutinins positive in 50%)
BAL, bronchoscopy	Immunocompromised, non-responding pneumonia

5. Other

Pulse oximetry: SpO2 <92% = hypoxemia - admit and treat
Chest CT: Higher sensitivity; used when CXR unclear or non-responding
Lung ultrasound: Point-of-care; useful in experienced hands

Severity Assessment

PSI (Pneumonia Severity Index) - Adults

Class I-II: Low risk - outpatient
Class III: Low-moderate - outpatient or brief hospitalization
Class IV-V: High risk - hospitalize

CURB-65 Score (Adults)

Criterion	Score
Confusion	1
Urea >7 mmol/L	1
Respiratory rate ≥30/min	1
BP <90 systolic or ≤60 diastolic	1
Age 65 or older	1

Score 0-1: Low risk - outpatient
Score 2: Intermediate - consider hospitalization
Score 3-5: High risk - hospitalize; score ≥4 consider ICU

Severe CAP (Requires ICU) Criteria

Major criteria (any 1 = ICU):

Need for mechanical ventilation
Septic shock requiring vasopressors

Minor criteria (3 or more = ICU):

RR ≥30/min
PaO2/FiO2 <250
Multilobar infiltrates
Confusion/disorientation
Urea >20 mg/dL
WBC <4000/mm³
Platelets <100,000/mm³
Hypothermia <36°C
Hypotension requiring aggressive fluids

Management

General Principles

Assess severity - decide: outpatient vs. ward vs. ICU
Start empirical antibiotics promptly (within 4 hours of diagnosis)
Narrow antibiotic therapy once pathogen identified
Supportive care: O2, fluids, antipyretics, physiotherapy

Antibiotic Therapy

Children (WHO/IAP Guidelines)

Severity	Setting	Drug
Pneumonia (mild)	Outpatient	Oral amoxicillin 40-45 mg/kg/day ÷ 2-3 doses × 5 days
Severe pneumonia	Hospital	Ampicillin IV 200 mg/kg/day ÷ 4 doses + Gentamicin IV 7.5 mg/kg/day
Very severe pneumonia	ICU	Cefotaxime/Ceftriaxone IV ± Vancomycin (if MRSA suspected)
Atypical (Mycoplasma, Chlamydia)	Any	Azithromycin 10 mg/kg day 1, then 5 mg/kg days 2-5
S. aureus (necrotizing)	ICU	Cloxacillin + Gentamicin; Vancomycin if MRSA
Neonatal	NICU	Ampicillin + Gentamicin empirically

Adults (CAP - Goldman-Cecil / IDSA Guidelines)

Setting	Regimen
Outpatient, healthy	Amoxicillin OR Doxycycline OR Azithromycin × 5 days
Outpatient, comorbidities	Respiratory fluoroquinolone (levofloxacin, moxifloxacin) OR β-lactam + macrolide
Inpatient, non-severe	β-lactam + macrolide OR respiratory fluoroquinolone
Inpatient, severe (ICU)	β-lactam (ceftriaxone) + macrolide OR β-lactam + fluoroquinolone
MRSA suspected	Add Vancomycin or Linezolid
Pseudomonas risk	Anti-pseudomonal β-lactam (pip-tazo, cefepime) + fluoroquinolone
Legionella	Fluoroquinolone OR Azithromycin

Duration: Minimum 5 days for most; 7 days for MRSA/Pseudomonas; until clinically stable.

Supportive Treatment

Measure	Details
Oxygen	Target SpO2 94-98%; via nasal cannula, face mask, or HFNC
IV fluids	Maintain hydration; correct dehydration
Antipyretics	Paracetamol for fever and comfort
Nutritional support	Crucial in malnourished children
Chest physiotherapy	For secretion clearance
Bronchodilators	If wheeze/bronchospasm present
NIV/CPAP	Hypoxic respiratory failure
Mechanical ventilation	Respiratory failure not responding to NIV

Complications

Complication	Key Points
Parapneumonic effusion	Occurs in up to 60% of CAP; most resolve spontaneously
Empyema thoracis	Pus in pleural space (3-5% of CAP); chest tube drainage required
Lung abscess	Cavitation due to necrosis; S. aureus, anaerobes, Klebsiella
Pneumatocele	Thin-walled air cyst in children; S. aureus; usually resolves
Pneumothorax	Especially with S. aureus, Pneumocystis
Respiratory failure	Type 1 (hypoxemia); Type 2 (hypercapnia) in severe disease
Septicemia/bacteremia	~10-15%; risk of metastatic infection
Atrial fibrillation	~20-25% of hospitalized adults
Myocardial ischemia/heart failure	Acute cardiac events with severe pneumonia
ARDS	Diffuse alveolar damage - bilateral infiltrates, PaO2/FiO2 <300
Pleural adhesions	Long-term sequel of empyema
Bronchiectasis	After recurrent/severe pneumonia; especially adenoviral in children
Death	Mortality ~6% during hospitalization; ~15% by 1 month for hospitalized adults

Specific Types

Staphylococcal Pneumonia (Ghai Emphasizes)

More common in infants <1 year and post-influenza
Very rapid progression; bilateral; necrotizing
Features: high fever, toxemia, respiratory distress
CXR: rapidly changing patchy consolidation → pneumatoceles, pyopneumothorax
Treatment: Cloxacillin (if MSSA) or Vancomycin (if MRSA) + supportive

Pneumococcal Pneumonia

Classic lobar pneumonia; sudden onset with rigor
Rusty sputum (blood-tinged); pleuritic chest pain
Lobar consolidation on CXR
Responds to amoxicillin/penicillin (unless resistant)

Mycoplasma Pneumonia (Walking Pneumonia)

School-age children, young adults
Gradual onset: headache, malaise, low-grade fever, then dry persistent cough
CXR: worse than clinical signs (bilateral interstitial/reticulonodular infiltrates)
Cold agglutinins positive in ~50%
Treatment: Azithromycin (macrolides) or doxycycline; β-lactams ineffective

Aspiration Pneumonia

Risk: altered consciousness, dysphagia, GERD, recumbency
Usually involves right lower lobe (or right middle lobe in upright aspiration)
Causes lung abscess/empyema
Treatment: Cover anaerobes - amoxicillin-clavulanate or clindamycin

Prevention

Strategy	Details
Pneumococcal vaccine (PCV13/PCV15/PCV20)	Routine childhood immunization; also adults >65 years
H. influenzae type b vaccine (Hib)	Routine childhood; drastically reduced Hib pneumonia
Influenza vaccine	Annual; children >6 months, elderly, high-risk groups
COVID-19 vaccine	Prevents SARS-CoV-2 pneumonia
Breastfeeding	Reduces risk significantly in infants
Malnutrition prevention	Vitamin A, zinc supplementation (reduces pneumonia risk in children)
Reducing indoor air pollution	Smoke exposure major risk factor in developing countries
Hand hygiene	Reduces transmission

Prognosis

Most healthy children and adults recover fully with treatment
Mortality for hospitalized CAP: ~6% in hospital; ~15% by 1 month
Poor prognostic factors:
- Age <2 months or >65 years
- Malnutrition / immunocompromised
- Multilobar involvement
- Bacteremia
- Delayed treatment
- Resistant organisms
- ARDS/respiratory failure
- Underlying comorbidities (COPD, heart failure, renal failure)
Radiographic clearance may lag 4-8 weeks behind clinical recovery (especially in elderly)

Summary - Key Points for Exams (Ghai-style)

Feature	Point
Most common cause in children	S. pneumoniae
Most common viral cause in infants	RSV
Most common cause of walking pneumonia	Mycoplasma pneumoniae
Rusty sputum	Pneumococcal pneumonia
Pneumatoceles	Staphylococcal pneumonia
Currant jelly sputum	Klebsiella pneumoniae
Afebrile pneumonia in infancy	Chlamydia trachomatis
Hyponatremia + pneumonia	Legionella pneumophila
WHO tachypnea threshold (2-12 months)	≥50 breaths/min
WHO tachypnea threshold (1-5 years)	≥40 breaths/min
First-line in mild childhood CAP	Oral amoxicillin
Atypical organisms - drug of choice	Azithromycin
MRSA pneumonia	Vancomycin or Linezolid

Sources: Goldman-Cecil Medicine 22e (International Edition); Fishman's Pulmonary Diseases and Disorders; Murray & Nadel's Textbook of Respiratory Medicine - all available in this library. The Ghai (OP Ghai Essential Pediatrics) textbook is not in the library database; this content is structured to match Ghai's chapter organization and Indian pediatric context.

This is a shared conversation. Sign in to Orris to start your own chat.